If Sanofi don’t licence DEP-Cabazitaxel and DEP-Docetaxel, and Pfizer don’t licence DEP-Irinotecan, and it appears neither want them after years of confidential sharing of data by Starpharma, IMO there’s next to zero chance of a 3rd party licencing any of the three.
Starpharma do not have the funds and will not be able to raise the large funds (on reasonable terms) required to conduct a single Phase 3 trial themselves. So where does that leave Starpharma?
P.S. To be fair they could theoretically raise $100m for a single modest Phase 3 trial, but I would guesstimate SPL would have to issue 1.2 billion shares at 8 cents each to raise that amount.
- Forums
- ASX - By Stock
- SPL
- Ann: Positive DEP Cabazitaxel Phase 2 Results in Multiple Cancer
Ann: Positive DEP Cabazitaxel Phase 2 Results in Multiple Cancer, page-74
Featured News
Add SPL (ASX) to my watchlist
|
|||||
Last
9.5¢ |
Change
0.008(9.20%) |
Mkt cap ! $39.14M |
Open | High | Low | Value | Volume |
9.0¢ | 9.5¢ | 8.8¢ | $334.2K | 3.710M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 50354 | 9.4¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
9.5¢ | 22908 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 760087 | 0.089 |
2 | 147200 | 0.087 |
3 | 118061 | 0.086 |
3 | 220000 | 0.085 |
1 | 100000 | 0.084 |
Price($) | Vol. | No. |
---|---|---|
0.095 | 22908 | 2 |
0.096 | 5000 | 1 |
0.099 | 6837 | 1 |
0.100 | 71848 | 3 |
0.105 | 370000 | 2 |
Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
Featured News
SPL (ASX) Chart |
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
SPONSORED BY The Market Online